TP53 and endometrial cancer: <h4>Objectives</h4>The objective of this study was to evaluate the efficacy of pembrolizumab and lenvatinib in recurrent endometrial cancer (EC) by platinum resistance status and p53 status, and to compare outcomes between patients who started lenvatinib at doses of 10 mg or less versus standard starting doses.<h4>Methods</h4>A retrospective study was conducted in patients with recurrent EC treated with pembrolizumab and lenvatinib between March 2019 and February 2023.